{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-024943","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.251425+00:00","generated_at":"2026-05-15T06:33:36.087514+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vistagen grants 75,000-share options to CEO, CFO, and three other executives at $0.5358","bullets":["Options granted to five executives: CEO Shawn Singh, CLO Reid Adler, CDO Elissa Cote, COO Joshua Prince, CFO Nick Tressler.","Each option covers 75,000 shares; exercise price $0.5358 per share.","Vesting: 25% at 6 months, then 25% every 6 months thereafter, fully vested in 2 years.","Granted under Amended and Restated 2019 Omnibus Equity Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-024943","json":"https://secwatch.observer/filing/0001628280-26-024943.json","markdown":"https://secwatch.observer/filing/0001628280-26-024943.md","text":"https://secwatch.observer/filing/0001628280-26-024943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026024943/0001628280-26-024943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026024943/vtgn-20260407.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:33:36.087514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}